Alzheimer Europe 2025: Prioritising Alzheimer’s Disease policy in Europe
Building upon the findings of a recent CRA report, which synthesised insights from a roundtable of AD experts, Prioritising Alzheimer’s disease policy in...
Industries
Life Sciences
We bring clarity to complex challenges.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Engagements
- 01Evaluating unintended impacts of the IRA’s Medicare Drug Price Negotiation Program on small and large molecule medicinesA leading pharmaceutical company sought support from CRA Life Sciences experts in analyzing the patient, health system, and innovation implications of the IRA'sView engagement
- 02Developing an evidence-based framework for sustainable NCCP funding and address global disparities in implementation and outcomesA leading pharmaceutical company sought CRA Life Sciences experts to gain a deeper understanding of how governments plan and finance national cancer strategiesView engagement
- 03Mapping and assessing national impacts of JCAs across EuropeCRA Life Science experts were retained by a client to provide support on the impact of the EU HTA regulation and the associated JCAs on national HTA systems.View engagement
Contact a Life Sciences expert.
See all Life Sciences expertsUpcoming events
GAR Live: Damages
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
World EPA Congress 2026
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
Recent events
What Happens if U.S. Pharmaceutical Prices Become the World’s Benchmark?
The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S....
Sex and Gender in the Patient Journey: Lessons from Alzheimer’s Disease Webinar
Tunahan Kirabali is a speaker during the webinar about sex and gender differences in the Alzheimer’s patient journey highlighting implications for clinical...